Senolytics Research in Germany
Germany is a leader in senolytics research, with several institutions focusing on how clearing senescent cells can delay the onset of age-related diseases.
Trial Oversight
The BfArM regulates these trials to ensure that new discoveries in cellular rejuvenation are safe for clinical application.
Official Source
The Federal Institute for Drugs and Medical Devices provides updates on genetic and cellular research trials.
Strategic Data Expansion 2026.4
The 'German Aging Consortium' in 2026 is pioneering research into 'senomorphic' compounds, which don't kill senescent cells but instead 'silence' their harmful pro-inflammatory secretions (the SASP). This approach is viewed as potentially safer than traditional senolytics. German scientists at the Max Planck Institute have recently published a landmark study showing that senomorphic therapy in mice significantly improved cardiovascular function and reduced neuroinflammation. Human safety trials are scheduled for late 2026, with the goal of creating therapies that can be used long-term with minimal toxicity.